Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 9 · below the Ichimoku cloud · RSI 32 · MACD below its signal · 7% above its 52-week low
| 6.55 | 52-week high | +164.65% |
| 4.08 | Previous month high | +64.85% |
| 2.97 | Previous week high | +20.20% |
| 2.86 | Previous month low | +15.35% |
| 2.70 | R3 (classic) | +9.09% |
| 2.66 | Previous week low | +7.47% |
| 2.61 | R2 (classic) | +5.25% |
| 2.54 | R1 (classic) | +2.63% |
| 2.51 | Previous day high | +1.41% |
| 2.48 | Price now | |
| 2.44 | Pivot | −1.21% |
| 2.38 | S1 (classic) | −3.84% |
| 2.35 | Previous day low | −5.05% |
| 2.32 | 52-week low | −6.26% |
| 2.28 | S2 (classic) | −7.68% |
| 2.22 | S3 (classic) | −10.30% |
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $4.3M | 0.01% | 1.23M | −15% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a SANA trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 8.8 | -5.0 | -31.6 | 14.2 | 0.3 | 5.8 | -10.3 | 23.6 | -24.7 | -15.1 | −39.2% | ||
| 2025 | 97.5 | -18.9 | -35.6 | 13.1 | 14.2 | 25.8 | 48.7 | -24.6 | 16.0 | 39.4 | -13.1 | -5.3 | +149.7% |
| 2024 | 34.6 | 82.9 | -0.4 | -10.0 | -16.7 | -27.2 | 11.5 | -0.7 | -31.2 | -15.9 | -20.6 | -41.4 | −60.0% |
| 2023 | 15.4 | -19.5 | -10.9 | 61.8 | 13.8 | -1.0 | -1.7 | -8.7 | -27.7 | -23.5 | 37.2 | 0.5 | +3.3% |
| 2022 | -43.4 | -26.3 | 27.9 | -8.6 | -32.1 | 25.3 | 3.9 | 1.9 | -11.9 | -3.3 | -14.0 | -20.8 | −74.5% |
| 2021 | 8.9 | -35.8 | -2.5 | -6.2 | -17.1 | 47.3 | -6.1 | -7.9 | -8.3 | -18.6 | −49.6% |
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 4, 2026 | Bishop Hans EdgarDirector | Stock Award(Grant) at price 0.00 per share. | 8.7K | — |
| Aug 25, 2026 | Patel Dhavalkumar DhirajlalOfficer | — | 125K | — |
| Jul 5, 2026 | Bishop Hans EdgarDirector | Stock Award(Grant) at price 0.00 per share. | 6.3K | — |
| Apr 5, 2026 | Bishop Hans EdgarDirector | Stock Award(Grant) at price 0.00 per share. | 7.8K | — |
| Mar 5, 2026 | Wyrick Susan DOfficer | — | 13.7K | — |
| Mar 5, 2026 | Harr Steve M.D.Chief Executive Officer | — | 91.7K | — |
| Mar 1, 2026 | Wyrick Susan DOfficer | — | 1.5K | — |
| Jan 4, 2026 | Bishop Hans EdgarDirector | Stock Award(Grant) at price 0.00 per share. | 6.2K | — |
| Jan 1, 2026 | Wyrick Susan DChief Financial Officer | — | 7.5K | — |
| Dec 11, 2025 | Wyrick Susan DChief Financial Officer | — | 3.4K | — |
| Dec 2, 2025 | Wyrick Susan DChief Financial Officer | — | 20K | — |
| Oct 5, 2025 | Bishop Hans EdgarDirector | Stock Award(Grant) at price 0.00 per share. | 5.6K | — |
| Jul 6, 2025 | Bishop Hans EdgarDirector | Stock Award(Grant) at price 0.00 per share. | 7.8K | — |
| Apr 6, 2025 | Bishop Hans EdgarDirector | Stock Award(Grant) at price 0.00 per share. | 16.3K | — |
| Mar 6, 2025 | Cassidy Bernard JGeneral Counsel | — | 11K | — |
| Mar 6, 2025 | Wyrick Susan DChief Financial Officer | — | 3.3K | — |
| Mar 6, 2025 | Harr Steve M.D.Chief Executive Officer | — | 50K | — |
| Feb 27, 2025 | Wyrick Susan DChief Financial Officer | — | 1.5K | — |
| Jan 7, 2025 | Fmr LlcBeneficial Owner of more than 10% of a Class of Security | Sale at price 4.30 per share. | 290.9K | $1.25M |
| Jan 5, 2025 | Bishop Hans EdgarDirector | Stock Award(Grant) at price 0.00 per share. | 14.3K | — |
Buy / hold / sell counts
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company has a strategic collaboration with Mayo Clinic for the development of SC451, a hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.